Form 4: Halozyme Therapeutics Director Matthew L. Posard Sells Shares in Multiple Transactions

Director Matthew L. Posard of Halozyme Therapeutics, Inc. [HALO] executed multiple sales of common stock between August 12 and August 14, 2024, reducing his holdings.

Summary

• On August 12, 2024, Matthew L. Posard, a director at Halozyme Therapeutics, sold 10,000 shares of common stock at a weighted average price of $55.723 per share.
• The sales prices ranged from $55.70 to $55.825.
• On August 13, 2024, Posard sold another 10,000 shares at a weighted average price of $56.193 per share, with prices ranging from $56.058 to $56.26.
• On August 14, 2024, Posard sold 9,881 shares at $57.7 per share.
• Following these transactions, Posard directly owns 69,874 shares of Halozyme Therapeutics common stock.
• This includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock sales by a company director. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information about insider transactions.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency to the market regarding the transactions of company insiders.

Stakeholder Impact

• Shareholders may interpret the stock sales as a lack of confidence by the director, although the reasons for the sale are not disclosed.

Key Dates